Factors associated with initial or subsequent choice of biologic disease-modifying antirheumatic drugs for treatment of rheumatoid arthritis
Abstract Background Biologic disease-modifying antirheumatic drugs (DMARDs) are increasingly used for rheumatoid arthritis (RA) treatment. However, little is known based on contemporary data about the factors associated with DMARDs and patterns of use of biologic DMARDs for initial and subsequent RA...
Main Authors: | Yinzhu Jin, Rishi J. Desai, Jun Liu, Nam-Kyong Choi, Seoyoung C. Kim |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2017-07-01
|
Series: | Arthritis Research & Therapy |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13075-017-1366-1 |
Similar Items
-
Treatment adherence to disease-modifying antirheumatic drugs in Chinese patients with rheumatoid arthritis
by: Xia Y, et al.
Published: (2016-05-01) -
Lipid profiles in rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs
by: Anna Filipowicz-Sosnowska, et al.
Published: (2014-06-01) -
Conventional synthetic disease-modifying antirheumatic drug use by race/ethnicity and factors associated with initiating biologics in Malaysian patients with rheumatoid arthritis
by: Suad Mohammed, et al.
Published: (2019-01-01) -
Preferences of patients with rheumatoid arthritis regarding disease-modifying antirheumatic drugs: a discrete choice experiment
by: van Heuckelum M, et al.
Published: (2019-07-01) -
Recent evidence comparing combination of conventional synthetic disease-modifying antirheumatic drugs with biologic disease-modifying antirheumatic drugs in rheumatoid arthritis
by: Abhishek Zanwar, et al.
Published: (2017-01-01)